phrykt

Recursion Pharmaceuticals, Inc. (RXRX): who owns it and who trades it

As of Nov 16, 2026, RXRX insiders reported 35 open-market sales worth $7.6M and no purchases in the last 12 months, with 100% of the sale value made under pre-set 10b5-1 plans. The largest seller was Blake Borgeson (Director), with $4.5M. 5 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Recursion Pharmaceuticals

From the latest filings

Overall: more buying than selling. Famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns RXRX

341 funds and institutions reported RXRX shares worth $1.3B at the end of Q2 2026, about 68% of the company. The largest holder is BlackRock, Inc. with 9.4%.

Funds and institutions (13F) 68%Everyone else 32%

10 largest owners, by share of the company

BlackRock, Inc.9.4%
ARK Investment Management LLC7.7%
State Street Corp6.5%
Vanguard Portfolio Management LLC5.8%
Baillie Gifford & Co4.4%
Vanguard Capital Management LLC4.3%
Geode Capital Management, LLC2.6%
Softbank Group Corp.2.5%
MIC Capital Management UK LLP1.8%
UBS Group AG1.7%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BlackRock, Inc.50.30M9.40%$185M+16%
ARK Investment Management LLC41.34M7.72%$152M+3%
State Street Corp34.71M6.48%$127M+22%
Vanguard Portfolio Management LLC31.13M5.82%$114M+37%
Baillie Gifford & Co23.49M4.39%$86.2M-1%
Vanguard Capital Management LLC22.77M4.25%$83.6M+2%
Geode Capital Management, LLC13.82M2.58%$50.7M+13%
Softbank Group Corp.13.64M2.55%$50MNo change
MIC Capital Management UK LLP9.64M1.80%$35.4MNo change
UBS Group AG8.95M1.67%$32.8M+75%
Norges Bank6.83M1.28%$25.1M–
Data Collective IV GP, LLC5.94M1.11%$21.8MNo change
Amova Asset Management Americas, Inc.5.51M1.03%$20.2M+2%
Sumitomo Mitsui Trust Group, Inc.5.51M1.03%$20.2M+2%
Northern Trust Corp4.76M0.89%$17.5M+20%
Marshall Wace, LLP4.71M0.88%$17.3M+64%
Charles Schwab Investment Management Inc4.14M0.77%$15.2M+9%
Sixth Street Partners Management Company, L.P.4.14M0.77%$15.2M–
DCVC Opportunity Fund II GP, LLC3.95M0.74%$14.5MNo change
Goldman Sachs Group Inc3.92M0.73%$14.4M-35%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, RXRX insiders reported $0 of open-market purchases and $7.6M of sales. 100% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$7.6M
35 trades, 6 people
Sales under a 10b5-1 plan
100%
Share of sale value
Latest trade
Nov 3, 2026
Filed Nov 4, 2026

Purchases and sales by month

$2M$2MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 3, 2026Blake BorgesonDirectorSale plan40,000$3.88$155KForm 4
Oct 6, 2026Blake BorgesonDirectorSale plan50,000$4.84$242KForm 4
Oct 6, 2026Robert HershbergDirectorSale plan25,000$5.00$125KForm 4
Sep 8, 2026Najat KhanCEOSale plan22,408$3.52$78.9KForm 4
Sep 1, 2026Blake BorgesonDirectorSale plan30,000$3.34$100KForm 4
Aug 4, 2026Blake BorgesonDirectorSale plan30,000$3.25$97.5KForm 4
Jul 7, 2026Blake BorgesonDirectorSale plan40,000$3.96$158KForm 4
Jun 18, 2026Namandje BumpusDirectorSale plan3,963$3.18$12.6KForm 4
Jun 5, 2026Christopher GibsonDirectorSale plan40,000$3.62$145KForm 4
Jun 5, 2026Najat KhanCEOSale plan23,588$3.58$84.4KForm 4
Jun 3, 2026Namandje BumpusDirectorSale plan4,386$3.54$15.5KForm 4
Jun 2, 2026Blake BorgesonDirectorSale plan30,000$3.68$110KForm 4
May 22, 2026Christopher GibsonDirectorSale plan40,000$3.08$123KForm 4
May 7, 2026Christopher GibsonDirectorSale plan40,000$3.37$135KForm 4
May 5, 2026Blake BorgesonDirectorSale plan30,000$3.52$106KForm 4
Apr 22, 2026Christopher GibsonDirectorSale plan40,000$3.61$144KForm 4
Apr 7, 2026Christopher GibsonDirectorSale plan40,000$3.10$124KForm 4
Apr 7, 2026Blake BorgesonDirectorSale plan30,000$3.10$93KForm 4
Mar 23, 2026Christopher GibsonDirectorSale plan40,000$3.25$130KForm 4
Mar 17, 2026Ben R TaylorCFOSale plan7,956$3.39$27KForm 4
Mar 9, 2026Najat KhanCEOSale plan28,298$3.35$94.8KForm 4
Mar 3, 2026Blake BorgesonDirectorSale plan170,000$3.46$588KForm 4
Feb 19, 2026Christopher GibsonDirectorSale plan40,000$3.46$138KForm 4
Feb 18, 2026Ben R TaylorCFOSale plan13,426$3.08$41.4KForm 4
Feb 4, 2026Christopher GibsonDirectorSale plan40,000$4.12$165KForm 4
Feb 3, 2026Blake BorgesonDirectorSale plan220,000$4.20$924KForm 4
Jan 20, 2026Christopher GibsonDirectorSale plan40,000$4.47$179KForm 4
Jan 6, 2026Blake BorgesonDirectorSale plan220,000$4.36$959KForm 4
Jan 5, 2026Christopher GibsonDirectorSale plan40,000$4.25$170KForm 4
Dec 29, 2025Ben R TaylorCFOSale plan21,383$4.18$89.4KForm 4
Dec 22, 2025Najat KhanDirectorSale plan124,403$4.41$549KForm 4
Dec 19, 2025Christopher GibsonCEOSale plan40,000$4.50$180KForm 4
Dec 4, 2025Christopher GibsonCEOSale plan40,000$4.63$185KForm 4
Dec 2, 2025Blake BorgesonDirectorSale plan220,000$4.37$961KForm 4
Nov 19, 2025Christopher GibsonCEOSale plan40,000$4.16$166KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Blake BorgesonDirector–$4.5MNov 3, 2026
Christopher GibsonChief Executive Officer, Director–$2MJun 5, 2026
Najat KhanChief R&D Commercial Officer, Director–$807KSep 8, 2026
Ben R TaylorChief Financial Officer–$158KMar 17, 2026
Robert HershbergDirector–$125KOct 6, 2026
Namandje BumpusDirector–$28.1KJun 18, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

RXRX short interest

Very high short interest. 22.8% of RXRX shares are sold short: about 1 share in 4. Over the last 12 reports the number of shares short went down 23%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 142.27M RXRX shares were sold short, 22.8% of the shares outstanding, down 12.1% from the report before. At the average daily volume of 23.33M shares, buying them all back would take about 6.1 trading days (days to cover).

Shares short, % of all shares

22.8%Jul 31Oct 3035.4%

Days to cover

6.1May 15Oct 3014.7

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 2026142.27M22.84%-12%23.33M6.1
Oct 15, 2026161.93M30.25%+3%36.46M4.4
Sep 30, 2026157.94M29.50%-12%25.77M6.1
Sep 15, 2026178.72M33.39%-0%14.22M12.6
Aug 31, 2026179.15M33.46%+1%16.90M10.6
Aug 14, 2026177.92M33.24%-2%13.31M13.4
Jul 31, 2026180.77M33.77%No change19.41M9.3
Jul 15, 2026180.76M–+5%26.88M6.7
Jun 30, 2026172.30M–-6%20.55M8.4
Jun 15, 2026184.02M–+12%22.01M8.4
May 29, 2026164.34M–-11%20.50M8.0
May 15, 2026184.44M–+8%13.89M13.3

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Recursion Pharmaceuticals company events

Recursion Pharmaceuticals filed 12 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Nov 2, 2026.

  1. Nov 2, 2026LeadershipThe Board of Directors of the Company, upon the recommendation from its Nominating and Corporate Governance Committee, increased the number of members of the Board from 9 to 10 and appointed Fred Hassan as Chair of the Board, effective immediately. Filing
  2. Oct 15, 2026AgreementRecursion Pharmaceuticals, Inc. entered into an underwriting agreement with Leerink Partners LLC, Goldman Sachs & Co. LLC, Morgan Stanley & Co. LLC and Evercore Group L.L.C. as representatives of the several underwriters named therein, relating to the offering of 61,540,000 shares of its Class A… Filing
  3. Sep 21, 2026AgreementRecursion Pharmaceuticals, Inc. and Tempus AI, Inc., acknowledging the value of (i) Tempus’s library of multimodal data and (ii) Recursion’s proprietary foundational RNA sequencing model, have entered into the following agreements: Amendment to Tempus Master Agreement On September 15, 2026, the… Filing
  4. Aug 5, 2026ResultsReleased financial results. Filing
  5. Jun 18, 2026VoteReported shareholder vote results. Filing
  6. May 6, 2026ResultsReleased financial results. Filing
  7. Apr 30, 2026LeadershipChristopher Gibson, Ph.D., Chair of the Board of Directors of Recursion Pharmaceuticals, Inc. and a member of the Research and Development Committee, Technology Committee, and the Corporate Social Responsibility Committee of the Board, informed the Company that he will not stand for re-election to… Filing
  8. Mar 25, 2026LeadershipRecursion Pharmaceuticals, Inc. announced that Vicki Goodman, M.D., will become Recursion’s Chief Medical Officer effective April 6, 2026, as David Mauro, M.D., Ph.D. transitions out of the role. Filing
  9. Feb 25, 2026ResultsReleased financial results. Filing
  10. Jan 12, 2026AnnouncementShared information with investors. Filing
  11. Dec 8, 2025AnnouncementRecursion Pharmaceuticals, Inc. issued a press release announcing Phase 1b/2 data from the ongoing TUPELO trial of REC-4881, an investigational allosteric MEK1/2 inhibitor for familial adenomatous polyposis (FAP). Filing
  12. Nov 26, 2025AnnouncementRecursion Pharmaceuticals, Inc. filed a prospectus supplement dated November 26, 2025 and an accompanying base prospectus, which are part of Recursion’s automatic “shelf” Registration Statement on Form S-3ASR (File No. 333-284878), which was previously filed on February 12, 2025 with the Securities… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Recursion Pharmaceuticals financials

Famous investors that hold RXRX

5 of the 50 well-known investors we track reported holding RXRX in their latest 13F filing. The largest position is Cathie Wood's, worth $185M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Cathie Wood · ARK Investment ManagementQ3 202644.75M$185M1.1%+8%
Israel Englander · Millennium ManagementQ3 20264.04M$16.7M0.0%+120%
Ken Griffin · Citadel AdvisorsQ3 20262.96M$12.2M0.0%+2206%
Steve Cohen · Point72 Asset ManagementQ3 2026238,435$985K0.0%New
Ray Dalio · Bridgewater AssociatesQ3 202696,596$399K0.0%+156%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named RXRX in the last 120 days.

FiledHolderFormStake
Nov 13, 2026ARK Investment Management LLC13G/A8.4%
Nov 13, 2026ARK Investment Management LLC13G/A8.4%
Nov 10, 2026STATE STREET CORPORATION13G5.6%
Nov 10, 2026STATE STREET CORPORATION13G5.6%

Questions about Recursion Pharmaceuticals, Inc. (RXRX) stock

Who owns the most RXRX stock?

The largest reported owner of Recursion Pharmaceuticals, Inc. (RXRX) is BlackRock, Inc., with 9.4% of the company. In total, 341 funds and institutions reported holding RXRX at the end of Q2 2026, together about 68% of the shares. See the largest owners.

Are RXRX insiders buying or selling?

In the last 12 months, RXRX insiders reported no open-market purchases and 35 sales worth $7.6M. The latest trade was on Nov 3, 2026. See every trade.

What is the short interest in RXRX?

As of Oct 30, 2026, 142.27M RXRX shares were sold short, 22.8% of the shares outstanding, down 12.1% from the report before. At the average daily volume of 23.33M shares, buying them all back would take about 6.1 trading days (days to cover). See the history.

Which famous investors hold RXRX?

5 of the 50 well-known investors we track reported RXRX in their latest 13F filing, including Cathie Wood, Israel Englander, Ken Griffin. The largest position is worth $185M. See all holders.

Executive pay

Recursion Pharmaceuticals's chief executive was paid a total of $9.6M for the year ended Dec 31, 2025, up 13% from $8.5M the year before. In the last 12 months, Recursion Pharmaceuticals's executives and directors bought no stock on the open market and sold $7.6M.

Chief executive, total pay$9.6MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$3.5MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$3.3MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.